Samsung Life Science Fund has announced an equity investment in Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of antibody-drug conjugates (ADCs).
Phrontline Biopharma is a company specialising in the development of innovative ADCs through its proprietary bispecific antibody and dual-linker payload platforms that enhance payload delivery efficiency and enable the simultaneous delivery of two payloads with balanced potency and complementary mechanisms of action through a branched-linker architecture. Through its technology, the company aims to overcome the limitations of single-payload, single-target ADCs, particularly in addressing resistance, tumour heterogeneity, and durability of response in treating a wide range of solid tumours.
Samsung Life Science Fund has been actively investing in biotechnology, and this investment further extends its commitment to advancing ADC technologies following earlier investments in Araris Biotech and Aimed Bio. With this addition, the Fund continues to diversify its portfolio and strengthen its focus on next-generation therapeutic modalities. Samsung Life Science Fund remains committed to advancing innovative treatments that address unmet medical needs and delivering meaningful impact for patients worldwide.
